Education
About Us
Working with TipRanks
Follow Us
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (DE:2TZ)
FRANKFURT:2TZ
2TZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.79 - €2.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.41B
Enterprise ValueN/A
Total Cash (Recent Filing)¥1.47B
Total Debt (Recent Filing)¥252.00M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Aug 13, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jul 02, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding200,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News
PremiumCompany Announcements
Tianjin Pharmaceutical Da Ren Tang Group Approves Strategic Equity DisposalPremiumCompany Announcements
Tianjin Pharmaceutical Updates on Net Proceeds Utilization
PremiumCompany Announcements
Tianjin Pharmaceutical Projects Significant Profit Growth for FY2024PremiumCompany Announcements
Tianjin Pharmaceutical Updates on Proposed Share Repurchase
PremiumCompany Announcements
Tianjin Pharmaceutical Completes Equity Disposal to Haleon
PremiumCompany Announcements
Tianjin Pharmaceutical Completes Major Capital Injection---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
2TZ FAQ
What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S lowest stock price was €1.79 and its highest was €2.39 in the past 12 months.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap is €2.41B.
When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date is Aug 13, 2025 which is in 100 days.
How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?
Currently, no data Available
Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?
According to Wall Street analysts Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price is currently Overvalued.
Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pays a Annually dividend of €0.155 which represents an annual dividend yield of N/A. See more information on Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S dividends here
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has 200,000,000 shares outstanding.
What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?
Currently, no hedge funds are holding shares in DE:2TZ
---
Company Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Zhong Xin Pharmaceutical Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
---
Technical Analysis
---